Moderna recoups part of losses as BofA raises PO ahead of key cancer vaccine readout
Mon 16:16
BUZZ-Moderna recoups part of losses as BofA raises PO ahead of key cancer vaccine readout ** Moderna MRNA.O shares jump 5% to $229, recouping from Friday's 7.8% drop
** Stock ~5.5% below 52-week high of $242.29 hit Thursday
** Rally driven by late-stage cancer vaccine data developed with Merck MRK.N; detailed results due October 24 at ESMO Congress
** BofA Global raises price objective to $220 from $200, maintains "neutral" rating; notes expected "positive data point" "already priced" in
** Focus at medical conference to be on magnitude of treatment's benefit and consistency across stages IIB-IV; to influence how much credit investors give to upcoming readouts in kidney, bladder and lung cancer
** Including session's move, MRNA up more than sevenfold YTD
(Reporting by Kamal Choudhury in Bengaluru)
Recent news on Moderna
See all newsTrading Day: Maximum pAIn
Moderna sheds about $24 billion as cancer vaccine data triggers 'sell-the-news' retreat
Merck/Moderna cancer vaccine cuts melanoma death or recurrence risk by 42%, shares fall (updated)
Brief: Merck Says Intismeran Plus Keytruda Significantly Reduced Risk Of Recurrence Or Death By 42%
Merck/Moderna cancer vaccine cuts risk of death or recurrence from melanoma by over 40%